These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33555963)

  • 1. Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?
    Tomao F; Caruso G; Musacchio L; Di Donato V; Petrella MC; Verrico M; Tomao S; Benedetti Panici P; Muzii L; Palaia I
    Expert Opin Drug Saf; 2021 Jun; 20(6):641-650. PubMed ID: 33555963
    [No Abstract]   [Full Text] [Related]  

  • 2. Capecitabine for treating head and neck cancer.
    Iqbal H; Pan Q
    Expert Opin Investig Drugs; 2016 Jul; 25(7):851-9. PubMed ID: 27144283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in paclitaxel combinations for treating cervical cancer.
    Della Corte L; Barra F; Foreste V; Giampaolino P; Evangelisti G; Ferrero S; Bifulco G
    Expert Opin Pharmacother; 2020 Apr; 21(6):663-677. PubMed ID: 32037907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine in locally advanced anal cancer, do we need randomised evidence?
    Chong LC; Healey T; Michele T; Price TJ
    Expert Rev Anticancer Ther; 2017 May; 17(5):411-416. PubMed ID: 28277833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
    Alsaloumi L; Shawagfeh S; Abdi A; Basgut B
    Oncol Res Treat; 2020; 43(12):694-702. PubMed ID: 32950984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
    Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
    J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in cervical cancer pharmacotherapies.
    Markman M
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):219-23. PubMed ID: 24490716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. A case report.
    Hindenburg AA; Matthews L
    Int J Gynecol Cancer; 2003; 13(6):898-900. PubMed ID: 14675331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
    McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
    Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
    Wu Z; Deng Y
    Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for advanced, recurrent, and metastatic cervical cancer.
    Moore DH
    J Natl Compr Canc Netw; 2008 Jan; 6(1):53-7. PubMed ID: 18267059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for recurrent cervical cancer.
    Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
    Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
    Torres A; Ramdial JL; Aguirre LE; Mahtani R; Vogel CL
    Breast Cancer Res Treat; 2019 Jul; 176(2):253-260. PubMed ID: 30900138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
    Reure J; Follana P; Gal J; Evesque L; Cavaglione G; Saint A; François E
    Oncology; 2016; 90(5):261-6. PubMed ID: 27097162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
    Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
    Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.
    Rashad N; Abdelhamid T; Shouman SA; Nassar H; Omran MA; El Desouky ED; Khaled H
    Clin Breast Cancer; 2020 Jun; 20(3):228-237. PubMed ID: 32005499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.